特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
955302

嚢胞性線維症:市場分析、疫学、市場予測 (2030年まで)

Cystic Fibrosis - Market Insights, Epidemiology, and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 219 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.81円
嚢胞性線維症:市場分析、疫学、市場予測 (2030年まで)
出版日: 2020年08月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文 219 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の主要6ヶ国における嚢胞性線維症 (CF) の市場規模は、2017年には19億4010万米ドルに達しました。

当レポートでは、世界の主要6カ国 - 米国、英国、ドイツ、フランス、イタリア、スペイン - における嚢胞性線維症 (CF) の疫学的動向と今後の見通しについて分析、疾患の概要や市場の基本構造、現在の治療法とアンメットニーズ、有病者数の動向見通し、年齢別・男女別・国別の詳細動向、上市済み/治験中の治療薬のプロファイル、世界全体/各国の市場規模 (2017~2030年)、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

目次

第1章 主な考察

第2章 エグゼクティブサマリー

第3章 組織

第4章 疫学と市場分析の手法

第5章 嚢胞性線維症 (CF):市場概要

  • 全体的な市場シェア構造 (2017年)
  • 全体的な市場シェア構造 (2030年)

第6章 嚢胞性線維症 (CF):市場概要

  • イントロダクション
  • 嚢胞性線維症の分類
  • 病態生理
  • 臨床徴候と症状
  • 診断

第7章 疫学と患者人口

  • 分析のポイント
  • 嚢胞性線維症 (CF) の総発症件数:主要6ヶ国 (6MM) の場合
  • 米国
    • 仮定と根拠
    • 嚢胞性線維症 (CF) の総発症件数
    • 嚢胞性線維症 (CF) の発症件数:男女別
    • 嚢胞性線維症 (CF) の発症件数:年齢別
    • 嚢胞性線維症 (CF) の発症件数:種類別
  • 欧州主要5ヶ国 (EU5)
  • ドイツ
    • 嚢胞性線維症 (CF) の総発症件数
    • 嚢胞性線維症 (CF) の発症件数:男女別
    • 嚢胞性線維症 (CF) の発症件数:年齢別
    • 嚢胞性線維症 (CF) の発症件数:種類別
  • フランス
  • イタリア
  • スペイン
  • 英国
    • 嚢胞性線維症 (CF) の総発症件数
    • 嚢胞性線維症 (CF) の発症件数:男女別
    • 嚢胞性線維症 (CF) の発症件数:年齢別
    • 嚢胞性線維症 (CF) の発症件数:種類別

第8章 嚢胞性線維症の治療方法

  • 投薬療法
  • 食事・運動療法
  • 気道クリアランス技術
  • 遺伝子治療
  • 手術

第9章 アンメットニーズ

第10章 上市済み医薬品

  • TRIKAFTA:Vertex Pharmaceuticals
    • 薬物の説明
    • その他の開発活動
    • 治験動向
    • 安全性・有効性
    • 製品のプロファイル
  • SYMDEKO:Vertex Pharmaceuticals
  • ORKAMBI:Vertex Pharmaceuticals
  • KALYDECO:Vertex Pharmaceuticals

第11章 新たな治療薬

  • 主要企業間の競合関係
  • MRT5005: Translate Bio Inc.
  • Nesolicaftor (PTI-428): Proteostasis Therapeutics
  • Dirocaftor (PTI-808): Proteostasis Therapeutics
  • VX-121: Vertex Pharmaceuticals, Inc.
  • ARO-ENaC: Arrowhead Pharmaceuticals
  • Eluforsen: ProQR Therapeutics
  • IONIS-ENaC-2.5: Ionis Pharmaceuticals
  • Ensifentrine: Verona Pharmaceuticals
  • ELX-02: Eloxx Pharmaceuticals, Inc.
  • VX-659: Vertex Pharmaceuticals
  • Posenacaftor (PTI-801): Proteostasis Therapeutics
  • Deutivacaftor (VX-561): Vertex Pharmaceuticals

第12章 嚢胞性線維症6の主要な市場分析

  • 主な調査結果
  • 6MMの嚢胞性線維症の市場規模

第13章 主要6ヶ国 (6MM) の市場の将来展望

第14章 国別の市場規模

  • 米国
    • 嚢胞性線維症 (CF):総市場規模
    • 治療薬別の市場規模
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国

第15章 市場促進要因

第16章 市場抑制要因

第17章 SWOT分析

第18章 市場アクセス

第19章 ケーススタディ

  • 遺伝子型3272-26A > G/Q493Xの嚢胞性線維症患者におけるイバカフトール治療後の陽性臨床転帰
  • 新生児の嚢胞性線維症
  • エジプト出身の患者における嚢胞性線維症の診断に関する症例報告
  • 嚢胞性線維症および膵炎の症例報告

第20章 業界の有識者 (KOL) の見解

第21章 付録

  • 分析手法

第22章:DelveInsightのサービス内容

第23章 免責事項

第24章:DelveInsightについて

図表

List of Tables

  • Table 1: Cystic Fibrosis Diagnosis - Clinical care guidelines
  • Table 2: Total cases of Cystic Fibrosis in 6MM (2017-2030)
  • Table 3: Total Prevalent cases of Cystic Fibrosis in the United States (2017-2030)
  • Table 4: Gender-specific cases of Cystic Fibrosis in the US (2017-2030)
  • Table 5: Age-specific cases of Cystic Fibrosis in the US (2017-2030)
  • Table 6: Type-specific cases of Cystic Fibrosis in the US (2017-2030)
  • Table 7: Total Prevalent cases of Cystic Fibrosis in Germany (2017-2030)
  • Table 8: Gender-specific cases of Cystic Fibrosis in Germany (2017-2030)
  • Table 9: Age-specific cases of Cystic Fibrosis in Germany (2017-2030)
  • Table 10: Type-specific cases of Cystic Fibrosis in Germany (2017-2030)
  • Table 11: Total Prevalent cases of Cystic Fibrosis in France (2017-2030)
  • Table 12: Gender-specific cases of Cystic Fibrosis in France (2017-2030)
  • Table 13: Age-specific cases of Cystic Fibrosis in France (2017-2030)
  • Table 14: Type-specific cases of Cystic Fibrosis in France (2017-2030)
  • Table 15: Total Prevalent cases of Cystic Fibrosis in Italy (2017-2030)
  • Table 16: Gender-specific cases of Cystic Fibrosis in Italy (2017-2030)
  • Table 17: Age-specific cases of Cystic Fibrosis in Italy (2017-2030)
  • Table 18: Type-specific cases of Cystic Fibrosis in Italy (2017-2030)
  • Table 19: Total Prevalent cases of Cystic Fibrosis in Spain (2017-2030)
  • Table 20: Gender-specific cases of Cystic Fibrosis in Spain (2017-2030)
  • Table 21: Age-specific cases of Cystic Fibrosis in Spain (2017-2030)
  • Table 22: Type-specific cases of Cystic Fibrosis in Spain (2017-2030)
  • Table 23: Total Prevalent cases of Cystic Fibrosis in the United Kingdom (2017-2030)
  • Table 24: Gender-specific cases of Cystic Fibrosis in the UK (2017-2030)
  • Table 25: Age-specific cases of Cystic Fibrosis in the UK (2017-2030)
  • Table 26: Type-specific cases of Cystic Fibrosis in the UK (2017-2030)
  • Table 27: TRIKAFTA, Clinical Trial Description, 2020
  • Table 28: SYMDEKO, Clinical Trial Description, 2020
  • Table 29: ORKAMBI, Clinical Trial Description, 2020
  • Table 30: KALYDECO, Clinical Trial Description, 2020
  • Table 31: MRT5005, Clinical Trial Description, 2020
  • Table 32: Nesolicaftor, Clinical Trial Description, 2020
  • Table 33: Dirocaftor, Clinical Trial Description, 2020
  • Table 34: VX-121, Clinical Trial Description, 2020
  • Table 35: ARO-ENaC, Clinical Trial Description, 2020
  • Table 36: Eluforsen, Clinical Trial Description, 2020
  • Table 37: IONIS-ENaC, Clinical Trial Description, 2020
  • Table 38: Ensifentrine, Clinical Trial Description, 2020
  • Table 39: ELX-02, Clinical Trial Description, 2020
  • Table 40: VX-659, Clinical Trial Description, 2020
  • Table 41: Posencaftor, Clinical Trial Description, 2020
  • Table 42: VX-561, Clinical Trial Description, 2020
  • Table 43: Market Size of Cystic Fibrosis in 6MM in USD Million (2017-2030)
  • Table 44: US Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Table 45: US Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Table 46: Market Size of Cystic Fibrosis in Germany, USD Millions (2017-2030)
  • Table 47: Germany Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Table 48: Market Size of Cystic Fibrosis associated in France, USD Millions (2017-2030)
  • Table 49: France Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Table 50: Market Size of Cystic Fibrosis in Italy, USD Millions (2017-2030)
  • Table 51: Italy Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Table 52: Market Size of Cystic Fibrosis in Spain, USD Millions (2017-2030)
  • Table 53: Spain Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Table 54: Market Size of Cystic Fibrosis in the UK, USD Millions (2017-2030)
  • Table 55: UK Market Size of Cystic Fibrosis in USD Million (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Classification of CFTR mutations according to their clinical consequences
  • Figure 3: ACMG recommended panel of 23 classic CF-causing mutations. These mutations include missense, stop, splicing, and frameshift mutations.
  • Figure 4: Classes of CFTR mutation
  • Figure 5: The multitude effects of Cystic Fibrosis on the body
  • Figure 6: Age-related presentations of cystic fibrosis
  • Figure 7: Causes of false-positive test results
  • Figure 8: Nasal potential difference tracking in subjects with cystic fibrosis (left) and in a healthy individual (right)
  • Figure 9: Hierarchy for the diagnosis of cystic fibrosis.
  • Figure 10: Total cases of Cystic Fibrosis in 6MM (2017-2030)
  • Figure 11: Total Prevalent cases of Cystic Fibrosis in the United States (2017-2030)
  • Figure 12: Gender-specific cases of Cystic Fibrosis in the US (2017-2030)
  • Figure 13: Age-specific cases of Cystic Fibrosis in the US (2017-2030)
  • Figure 14: Type-specific cases of Cystic Fibrosis in the US (2017-2030)
  • Figure 15: Total Prevalent cases of Cystic Fibrosis in Germany (2017-2030)
  • Figure 16: Gender-specific cases of Cystic Fibrosis in Germany (2017-2030)
  • Figure 17: Age-specific cases of Cystic Fibrosis in Germany (2017-2030)
  • Figure 18: Type-specific cases of Cystic Fibrosis in Germany (2017-2030)
  • Figure 19: Total Prevalent cases of Cystic Fibrosis in France (2017-2030)
  • Figure 20: Gender-specific cases of Cystic Fibrosis in France (2017-2030)
  • Figure 21: Age-specific cases of Cystic Fibrosis in France (2017-2030)
  • Figure 22: Type-specific cases of Cystic Fibrosis in France (2017-2030)
  • Figure 23: Total Prevalent cases of Cystic Fibrosis in Italy (2017-2030)
  • Figure 24: Gender-specific cases of Cystic Fibrosis in Italy (2017-2030)
  • Figure 25: Age-specific cases of Cystic Fibrosis in Italy (2017-2030)
  • Figure 26: Type-specific cases of Cystic Fibrosis in Italy (2017-2030)
  • Figure 27: Total Prevalent cases of Cystic Fibrosis in Spain (2017-2030)
  • Figure 28: Gender-specific cases of Cystic Fibrosis in Spain (2017-2030)
  • Figure 29: Age-specific cases of Cystic Fibrosis in Spain (2017-2030)
  • Figure 30: Type-specific cases of Cystic Fibrosis in Spain (2017-2030)
  • Figure 31: Total Prevalent cases of Cystic Fibrosis in the United Kingdom (2017-2030)
  • Figure 32: Gender-specific cases of Cystic Fibrosis in the UK (2017-2030)
  • Figure 33: Age-specific cases of Cystic Fibrosis in the UK (2017-2030)
  • Figure 34: Type-specific cases of Cystic Fibrosis in the UK (2017-2030)
  • Figure 35: Pharmacologic Treatment of CF with High/Substantial or High/Moderate Net Benefit
  • Figure 36: Unmet Needs
  • Figure 37: Market Size of Cystic Fibrosis in USD Million (2017-2030)
  • Figure 38: Market Size of Cystic Fibrosis in the US, USD Millions (2017-2030)
  • Figure 39: Market Size of Cystic Fibrosis in the US by therapies, USD Millions (2017-2030)
  • Figure 40: Market Size of Cystic Fibrosis in Germany, USD Millions (2017-2030)
  • Figure 41: Market Size of Cystic Fibrosis in Germany by therapies, USD Millions (2017-2030)
  • Figure 42: Market Size of Cystic Fibrosis in France, USD Millions (2017-2030)
  • Figure 43: Market Size of Cystic Fibrosis in France by therapies, USD Millions (2017-2030)
  • Figure 44: Market Size of Cystic Fibrosis in Italy, USD Millions (2017-2030)
  • Figure 45: Market Size of Cystic Fibrosis in Italy by therapies, USD Millions (2017-2030)
  • Figure 46: Market Size of Cystic Fibrosis in Spain, USD Millions (2017-2030)
  • Figure 47: Market Size of Cystic Fibrosis in Spain by therapies, USD Millions (2017-2030)
  • Figure 48: Market Size of Cystic Fibrosis in the UK, USD Millions (2017-2030)
  • Figure 49: Market Size of Cystic Fibrosis in the UK by therapies, USD Millions (2017-2030)
  • Figure 50: Market Drivers
  • Figure 51: Market Barriers
目次
Product Code: DIMI0268

DelveInsight's 'Cystic Fibrosis (CF) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Cystic Fibrosis (CF), historical and forecasted epidemiology as well as the market trends in the United States, and EU5 (Germany, Spain, Italy, France, and United Kingdom).

The Cystic Fibrosis (CF) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Cystic Fibrosis (CF) symptoms market size from 2017 to 2030 segmented by six major markets. The report also covers current Cystic Fibrosis (CF) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Study Period: 2017-2030

Cystic Fibrosis (CF) Disease Understanding and Treatment Algorithm

Cystic Fibrosis (CF) Overview

First identified nearly 80 years ago, cystic fibrosis (CF) is an autosomal recessive genetic disorder that causes damage to the lungs and the digestive system with the highest prevalence in Europe, North America, and Australia. A genetic mutation causes this disease in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR protein is a chloride-conducting trans-membrane conductance regulator belonging to the ABC transporter class. It helps in the transportation of chloride ions, thereby maintaining the electrochemical gradient as well as osmotic and fluid balance in the passageways.

A defect in CFTR protein due to an autosomal recessive mutation in the gene can have a wide range of debilitating consequences. The most common defect is highly viscous mucus that obstructs airway tracts which leads to difficulty in breathing. Moreover, it serves as a breeding ground for a huge range of bacterial infections like Staphylococcus aureus, Haemophilus influenza, and Pseudomonas aeruginosa. CFTR is present in other parts of the body as well; therefore, other consequences of such a mutation include malabsorption, pancreatic dysfunction, infertility, bowel obstruction, among many others.  

Cystic Fibrosis (CF) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Cystic Fibrosis (CF) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, and Europe.

The DelveInsight Cystic Fibrosis (CF) market report gives a thorough understanding of Cystic Fibrosis (CF) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Cystic Fibrosis (CF) symptoms of treatment algorithms and treatment guidelines for Cystic Fibrosis (CF) symptoms in the US, and Europe.

Earlier diagnostic tools relied on phenotype, with clinical recognition of characteristic signs and symptoms. Advancement in diagnostic capabilities facilitated the adoption of widespread CF newborn screening (NBS), wherein at least 64% of new CF diagnoses in the US were diagnosed in asymptomatic or minimally symptomatic infants. However, universal NBS was implemented in 2010 in the US, and many individuals born before 2010 have not been screened. The research and development over the last few years have contributed to the understanding of phenotypic and genotypic information of CFTR and has contributed to getting a clearer picture of the disease.

There is no cure for cystic fibrosis, but medications and other therapies can ease symptoms, reduce complications, and improve quality of life. Close monitoring and early, aggressive intervention are recommended to slow the progression of CF, which can lead to a longer life.

Medications used to treat patients with cystic fibrosis may include pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor, tezacaftor).

The FDA has approved TRIKAFTA, SYMDEKO, ORKAMBI and KALYDECO by Vertex Pharmaceuticals for Cystic Fibrosis (CF).

Cystic Fibrosis (CF) Epidemiology

The Cystic Fibrosis (CF) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The diagnosed prevalent cases of Cystic Fibrosis (CF) is increasing in 6MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Cystic Fibrosis (CF) symptoms epidemiology segmented as the Total Prevalent cases of Cystic Fibrosis (CF), Gender-specific cases of Cystic Fibrosis (CF), Age-specific cases of Cystic Fibrosis (CF), Type-specific cases of Cystic Fibrosis (CF). The report includes the prevalent scenario of Cystic Fibrosis (CF) symptoms in 6MM covering the United States, and EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) from 2017 to 2030.

Country Wise- Cystic Fibrosis (CF) Epidemiology

The epidemiology segment also provides the Cystic Fibrosis (CF) epidemiology data and findings across the United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom).

The total prevalent cases of Cystic Fibrosis (CF) associated in 6MM countries was 61,306 in 2017.

Cystic Fibrosis (CF) Drug Chapters

The drug chapter segment of the Cystic Fibrosis (CF) report encloses the detailed analysis of Cystic Fibrosis (CF) marketed drugs and early-stage (Phase-I, II, III) pipeline drugs. It also helps to understand the Cystic Fibrosis (CF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Cystic Fibrosis (CF) Emerging Drug

MRT5005: Translate Bio Inc.

MRT5005, a lead program for the lung, is the first clinical-stage mRNA product candidate designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization. MRT5005 is being developed to treat all patients with CF, regardless of the underlying genetic mutation, including those with limited or no CFTR protein.

VX-121: Vertex Pharmaceuticals

VX-121 is an orally administered CFTR corrector that helps fix and restore the function of defective CFTR protein. The corrected CFTR protein can then translocate to the cell surface where it performs the normal function and helps maintain the right balance of fluid in the airways. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a transmembrane protein in epithelial cells that plays a crucial role in ion transport across the cell, especially the transport of chloride and sodium ions.

Products detail in the report…

Cystic Fibrosis (CF) Market Outlook

The Cystic Fibrosis (CF) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Cystic Fibrosis (CF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Cystic Fibrosis (CF) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Cystic Fibrosis (CF) market in 6MM is expected to grow in the study period 2017-2030.

Cloning of CF Transmembrane conductance Regulator (CFTR) gene has provided a breakthrough in the understanding of the molecular basis of this disease. There are over 1,800 mutations of CFTR identified thus far, wherein 23 variants account for the majority of CF-causing mutations. The CF-causing mutations of CFTR can be grouped into classes depending on the physiological effect. Some mutations cause little or no protein to be made (Class I and IV), others create a defective protein that does not make it to the cell membrane (Class II), and others cannot be effectively regulated or conduct chloride (Class III and IV).

Classification of the mutations allows the development of specialized drugs to overcome the specific gene mutation. The most common CF mutation, F508del, is primarily considered to be a processing mutation. The F508del mutation removes a single amino acid from the CFTR protein. Without this building block, the CFTR protein cannot stay in the correct 3-D shape. The cell recognizes that the protein is not the right shape and disposes of it.

Approximately 44% of CF patients are homozygous for the F508del mutation (i.e., F508del/F508del), while around 41% are compound heterozygotes (i.e., F508del/other CF causing CFTR mutation), and about 15% have two non-F508del CF-causing CFTR mutations. Patients who are homozygous for F508del are said to have "classic CF." Patients with classic CF tend to be pancreatic insufficient and have more severe lung disease than CF patients with other mutations.

Key Findings

This section includes a glimpse of the Cystic Fibrosis (CF) market in 6MM. The market size of Cystic Fibrosis (CF) in the six major markets was USD 1,940.1 million in 2017.

The United States Market Outlook

This section provides the total Cystic Fibrosis (CF) market size and market size by therapies in the United States.

The United States accounts for the largest market size of Cystic Fibrosis (CF) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain).

EU-5 Countries: Market Outlook

The total Cystic Fibrosis (CF) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Cystic Fibrosis (CF) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Cystic Fibrosis (CF) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs. It also allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Cystic Fibrosis (CF) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II and III stage. It also analyses Cystic Fibrosis (CF) key players involved in developing targeted therapeutics.

Major players include Translate Bio, Inc., Proteostasis Therapeutics, Vertex Pharmaceuticals, and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Cystic Fibrosis (CF) emerging therapies.

Reimbursement Scenario in Cystic Fibrosis (CF)

Approaching reimbursement, proactively, can have a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Lumacaftor/ivacaftor was approved by the Food and Drug Administration (FDA) as a combination treatment for Cystic Fibrosis (CF) patients who are homozygous for the F508del mutation. Under the base-case, Lumacaftor/ivacaftor resulted in higher QALYs (7.29 vs. 6.84) but at a very high cost (USD 1,778,920.88) compared to usual care (USD 116,155.76) over 10 years. The ICER for base-case and worst-case scenarios were USD 3,655,352/QALY, and USD 8,480,265/QALY gained, respectively. In the base-case, lumacaftor/ivacaftor was cost-effective at a threshold of USD 150,000/QALY-gained when annual drug costs were lower than USD 4,153; the results were not substantially affected by the sensitivity analyses. The intervention produced substantial QALY gains but at an extremely high cost, resulting in an ICER that would not typically be covered by any insurer. Hence, Lumacaftor/ivacaftor's status as an orphan drug complicates coverage decisions.

Although CF is uncommon, it represents a significant economic burden. In 2013, CF-related hospital costs alone were estimated to exceed USD 1.1 billion. Institute for Clinical and Economic Review (ICER) reviewed the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) Database for US commercial health plan coverage policies for Trikafta, Kalydeco, Orkambi, Symdeko, developed by the Center for Evaluation of Value and Risk in Health.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Cystic Fibrosis (CF) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cystic Fibrosis (CF) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Cystic Fibrosis (CF) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Cystic Fibrosis (CF), explaining its causes, signs and symptoms, physiology and currently available therapies
  • Comprehensive insight has been provided into the Cystic Fibrosis (CF) epidemiology and treatment in the 6MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cystic Fibrosis (CF) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Cystic Fibrosis (CF) market; historical and forecasted is included in the report, covering drug outreach in the 6MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cystic Fibrosis (CF) market

Report Highlights:

  • In the coming years, Cystic Fibrosis (CF) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cystic Fibrosis (CF) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Cystic Fibrosis (CF). Launch of emerging therapies will significantly impact the Cystic Fibrosis (CF) market
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Cystic Fibrosis (CF)Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cystic Fibrosis (CF) Pipeline Analysis
  • Cystic Fibrosis (CF) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cystic Fibrosis (CF)Report Key Strengths

  • 11 years Forecast
  • 6MM Coverage
  • Cystic Fibrosis (CF) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cystic Fibrosis (CF)Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Cystic Fibrosis (CF) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Cystic Fibrosis (CF) total market Size as well as market Size by therapies across the 6MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 6MM and which country will have the largest Cystic Fibrosis (CF) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Cystic Fibrosis (CF) market is expected to grow in 6MM during the forecast period (2017-2030)?
  • What would be the Cystic Fibrosis (CF) market outlook across the 6MM during the forecast period (2017-2030)?
  • What would be the Cystic Fibrosis (CF) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Cystic Fibrosis (CF)?
  • What is the historical Cystic Fibrosis (CF) patient pool in six major markets covering the United States, and EU5 (Germany, Spain, France, Italy, UK)?
  • What would be the forecasted patient pool of Cystic Fibrosis (CF) in 6 major markets covering the United States, and EU5 (Germany, Spain, France, Italy, UK)?
  • What will be the growth opportunities in the 6MM with respect to the patient population pertaining to Cystic Fibrosis (CF)?
  • Out of all 6MM countries, which country would have the largest prevalent population of Cystic Fibrosis (CF) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 6MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Cystic Fibrosis (CF) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cystic Fibrosis (CF) in the USA, and Europe?
  • What are the Cystic Fibrosis (CF) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Cystic Fibrosis (CF)?
  • How many therapies are developed by each company for the treatment of Cystic Fibrosis (CF)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Cystic Fibrosis (CF)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cystic Fibrosis (CF) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cystic Fibrosis (CF) and their status?
  • What are the key designations that have been granted for the emerging therapies for Cystic Fibrosis (CF)?
  • What are the global historical and forecasted market of Cystic Fibrosis (CF)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Cystic Fibrosis (CF) market
  • To understand the future market competition in the Cystic Fibrosis (CF) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cystic Fibrosis (CF) in the US, and Europe (Germany, Spain, Italy, France, and the United Kingdom)
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cystic Fibrosis (CF) market
  • To understand the future market competition in the Cystic Fibrosis (CF) market

Table of Contents

1 Key Insights

2 Executive Summary

3 Organizations

4 Epidemiology and Market Methodology

5 Cystic Fibrosis: Market Overview at a Glance

  • 5.1 Total Market Share (%) Distribution of Cystic Fibrosis in 2017
  • 5.2 Total Market Share (%) Distribution of Cystic Fibrosis in 2030

6 Cystic Fibrosis: Market Overview at a Glance

  • 6.1 Introduction
  • 6.2 Classification of cystic fibrosis
  • 6.3 Pathophysiology
  • 6.4 Clinical signs and symptoms
  • 6.5 Diagnosis

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Total cases of Cystic Fibrosis in 6MM
  • 7.3 United States
    • 7.3.1 Assumptions and Rationale
    • 7.3.2 Total Prevalent cases of Cystic Fibrosis in the United States
    • 7.3.3 Gender-specific cases of Cystic Fibrosis in the United States
    • 7.3.4 Age-specific cases of Cystic Fibrosis in the United States
    • 7.3.5 Type-specific cases of Cystic Fibrosis in the United States
  • 7.4 EU5 Countries
    • 7.4.1 Assumptions and Rationale
  • 7.5 Germany
    • 7.5.1 Total Prevalent cases of Cystic Fibrosis in Germany
    • 7.5.2 Gender-specific cases of Cystic Fibrosis in Germany
    • 7.5.3 Age-specific cases of Cystic Fibrosis in Germany
    • 7.5.4 Type-specific cases of Cystic Fibrosis in Germany
  • 7.6 France
    • 7.6.1 Total Prevalent cases of Cystic Fibrosis in France
    • 7.6.2 Gender-specific cases of Cystic Fibrosis in France
    • 7.6.3 Age-specific cases of Cystic Fibrosis in France
    • 7.6.4 Type-specific cases of Cystic Fibrosis in France
  • 7.7 Italy
    • 7.7.1 Total Prevalent cases of Cystic Fibrosis in Italy
    • 7.7.2 Gender-specific cases of Cystic Fibrosis in Italy
    • 7.7.3 Age-specific cases of Cystic Fibrosis in Italy
    • 7.7.4 Type-specific cases of Cystic Fibrosis in Italy
  • 7.8 Spain
    • 7.8.1 Total Prevalent cases of Cystic Fibrosis in Spain
    • 7.8.2 Gender-specific cases of Cystic Fibrosis in Spain
    • 7.8.3 Age-specific cases of Cystic Fibrosis in Spain
    • 7.8.4 Type-specific cases of Cystic Fibrosis in Spain
  • 7.9 UK
    • 7.9.1 Total Prevalent cases of Cystic Fibrosis in the United Kingdom
    • 7.9.2 Gender-specific cases of Cystic Fibrosis in the United Kingdom
    • 7.9.3 Age-specific cases of Cystic Fibrosis in the United Kingdom
    • 7.9.4 Type-specific cases of Cystic Fibrosis in the United Kingdom

8 Treatment for Cystic Fibrosis

  • 8.1 Medications
  • 8.2 Diet and Exercise
  • 8.3 Airway clearance techniques
  • 8.4 Gene Therapy
  • 8.5 Surgery

9 Unmet Need

10 Marketed Drugs

  • 10.1 TRIKAFTA: Vertex Pharmaceuticals
    • 10.1.1 Drug Description
    • 10.1.2 Regulatory Milestones
    • 10.1.3 Other Development Activities
    • 10.1.4 Clinical Development
    • 10.1.5 Safety and Efficacy
    • 10.1.6 Product Profile
  • 10.2 SYMDEKO: Vertex Pharmaceuticals
    • 10.2.1 Drug Description
    • 10.2.2 Regulatory Milestones
    • 10.2.3 Other Development Activities
    • 10.2.4 Clinical Development
    • 10.2.5 Safety and Efficacy
    • 10.2.6 Product Profile
  • 10.3 ORKAMBI: Vertex Pharmaceuticals
    • 10.3.1 Drug Description
    • 10.3.2 Regulatory Milestones
    • 10.3.3 Other Development Activities
    • 10.3.4 Clinical Development
    • 10.3.5 Safety and Efficacy
    • 10.3.6 Product Profile
  • 10.4 KALYDECO: Vertex Pharmaceuticals
    • 10.4.1 Drug Description
    • 10.4.2 Regulatory Milestones
    • 10.4.3 Other Development Activities
    • 10.4.4 Clinical Development
    • 10.4.5 Safety and Efficacy
    • 10.4.6 Product Profile

11 Emerging Therapies

    • 11.1.1 Key Cross Competition
  • 11.2 MRT5005: Translate Bio Inc.
    • 11.2.1 Drug Description
    • 11.2.2 Other Development Activities
    • 11.2.3 Clinical Development
    • 11.2.4 Safety and Efficacy
    • 11.2.5 Product Profile
  • 11.3 Nesolicaftor (PTI-428): Proteostasis Therapeutics
    • 11.3.1 Drug Description
    • 11.3.2 Other Developmental Activities
    • 11.3.3 Clinical Development
    • 11.3.4 Safety and Efficacy
    • 11.3.5 Product Profile
  • 11.4 Dirocaftor (PTI-808): Proteostasis Therapeutics
    • 11.4.1 Drug Description
    • 11.4.2 Other Developmental Activities
    • 11.4.3 Clinical Development
    • 11.4.4 Safety and Efficacy
    • 11.4.5 Product Profile
  • 11.5 VX-121: Vertex Pharmaceuticals, Inc.
    • 11.5.1 Drug Description
    • 11.5.2 Other Developmental Activities
    • 11.5.3 Clinical Development
    • 11.5.4 Product Profile
  • 11.6 ARO-ENaC: Arrowhead Pharmaceuticals
    • 11.6.1 Drug Description
    • 11.6.2 Other Development Activities
    • 11.6.3 Clinical Development
    • 11.6.4 Safety and Efficacy
    • 11.6.5 Product Profile
  • 11.7 Eluforsen: ProQR Therapeutics
    • 11.7.1 Drug Description
    • 11.7.2 Other Development Activities
    • 11.7.3 Clinical Development
    • 11.7.4 Safety and Efficacy
    • 11.7.5 Product Profile
  • 11.8 IONIS-ENaC-2.5: Ionis Pharmaceuticals
    • 11.8.1 Drug Description
    • 11.8.2 Other Development Activities
    • 11.8.3 Clinical Development
    • 11.8.4 Safety and Efficacy
    • 11.8.5 Product Profile
  • 11.9 Ensifentrine: Verona Pharmaceuticals
    • 11.9.1 Drug Description
    • 11.9.2 Other Development Activities
    • 11.9.3 Clinical Development
    • 11.9.4 Safety and Efficacy
    • 11.9.5 Product Profile
  • 11.10. ELX-02: Eloxx Pharmaceuticals, Inc.
    • 11.10.1 Drug Description
    • 11.10.2 Other Developmental Activities
    • 11.10.3 Clinical Development
    • 11.10.4 Safety and Efficacy
    • 11.10.5 Product Profile
  • 11.11 VX-659: Vertex Pharmaceuticals
    • 11.11.1 Drug Description
    • 11.11.2 Other Development Activities
    • 11.11.3 Clinical Development
    • 11.11.4 Safety and Efficacy
    • 11.11.5 Product Profile
  • 11.12 Posenacaftor (PTI-801): Proteostasis Therapeutics
    • 11.12.1 Drug Description
    • 11.12.2 Other Developmental Activities
    • 11.12.3 Clinical Development
    • 11.12.4 Safety and Efficacy
    • 11.12.5 Product Profile
  • 11.13 Deutivacaftor (VX-561): Vertex Pharmaceuticals
    • 11.13.1 Drug Description
    • 11.13.2 Other Developmental Activities
    • 11.13.3 Clinical Development
    • 11.13.4 Safety and Efficacy
    • 11.13.5 Product Profile

12 Cystic Fibrosis 6 Major Market Analysis

  • 12.1 Key Findings
  • 12.2 Market Size of Cystic Fibrosis in 6MM

13 Six Major Market Outlook

14 United States Market Size

  • 14.1 Total Market Size of Cystic Fibrosis in the United States
  • 14.2 Total Market Size of Cystic Fibrosis by Therapies in the United States
  • 14.3 Germany
    • 14.3.1 Total market size of Cystic Fibrosis in Germany
    • 14.3.2 Total market size of Cystic Fibrosis by Therapies in Germany
  • 14.4 France
    • 14.4.1 Total market size of Cystic Fibrosis in France
    • 14.4.2 Total Market size of Cystic Fibrosis by Therapies in France
  • 14.5 Italy
    • 14.5.1 Total market size of Cystic Fibrosis in Italy
    • 14.5.2 Total Market size of Cystic Fibrosis by Therapies in Italy
  • 14.6 Spain
    • 14.6.1 Total Market Size of Cystic Fibrosis in Spain
    • 14.6.2 Total market size of Cystic Fibrosis by Therapies in Spain
  • 14.7 United Kingdom
    • 14.7.1 Total market size of Cystic Fibrosis in the United Kingdom
    • 14.7.2 Total market size of Cystic Fibrosis by Therapies in the UK

15 Market Driver

16 Market Barrier

17 SWOT Analysis

18 Market Access

Reimbursement

19 Case Study

  • 19.1 A case study on positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X
  • 19.2 A case study of Cystic Fibrosis in the Newborn
  • 19.3 A case report on the diagnosis of cystic fibrosis in a patient of Egyptian background
  • 19.4 A case report on Cystic Fibrosis and Pancreatitis

20 KOL Views

21 Appendix

  • 21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.